O	0	10	Randomized
O	10	11	,
O	12	23	Prospective
O	23	24	,
O	25	29	Open
O	29	30	-
O	30	35	label
O	36	41	Phase
O	42	45	III
O	46	51	Trial
O	52	61	Comparing
B-intervention	62	66	Mebo
I-intervention	67	75	Ointment
O	76	80	With
B-control	81	88	Biafine
I-control	89	94	Cream
O	95	98	for
O	99	102	the
O	103	113	Management
O	114	116	of
B-condition	117	122	Acute
I-condition	123	133	Dermatitis
O	134	140	During
O	141	153	Radiotherapy
O	154	157	for
O	158	164	Breast
O	165	171	Cancer
O	171	172	.

O	173	178	Acute
O	179	188	radiation
O	189	199	dermatitis
O	200	202	is
O	203	204	a
O	205	211	common
O	212	216	side
O	216	217	-
O	217	223	effect
O	224	226	of
O	227	239	radiotherapy
O	240	242	in
O	243	249	breast
O	250	256	cancer
O	257	260	and
O	261	264	has
O	265	266	a
O	267	275	profound
O	276	282	impact
O	283	285	on
O	286	294	patients
O	294	295	'
O	296	303	quality
O	304	306	of
O	307	311	life
O	311	312	,
O	313	316	due
O	317	319	to
O	320	324	pain
O	325	328	and
O	329	339	discomfort
O	339	340	.

O	341	344	The
O	345	348	aim
O	349	351	of
O	352	356	this
O	357	362	study
O	363	365	is
O	366	368	to
O	369	376	compare
O	377	380	the
O	381	387	effect
O	388	390	of
O	391	392	β
O	392	393	-
O	393	403	sitosterol
O	404	405	(
O	405	409	Mebo
O	409	410	)
O	411	419	ointment
O	420	422	to
O	423	432	trolamine
O	433	434	(
O	434	441	Biafine
O	441	442	)
O	443	448	cream
O	449	452	for
O	453	456	the
O	457	467	prevention
O	468	471	and
O	472	481	treatment
O	482	484	of
O	485	494	radiation
O	495	505	dermatitis
O	506	508	in
O	509	515	breast
O	516	522	cancer
O	523	531	patients
O	532	541	receiving
O	542	550	adjuvant
O	551	560	radiation
O	561	568	therapy
O	568	569	.

O	570	574	This
O	575	577	is
O	578	579	a
O	580	591	prospective
O	592	596	open
O	596	597	-
O	597	602	label
O	603	613	randomized
O	614	619	phase
O	620	623	III
O	624	629	study
O	630	639	developed
O	640	642	to
O	643	649	assess
O	650	653	the
O	654	662	efficacy
O	663	665	of
O	666	667	2
O	668	675	topical
O	676	682	agents
O	683	687	used
O	688	691	for
O	692	702	management
O	703	705	of
O	706	711	acute
O	712	721	radiation
O	722	732	dermatitis
O	732	733	.

B-eligibility	734	740	Female
I-eligibility	741	747	breast
I-eligibility	748	754	cancer
I-eligibility	755	763	patients
I-eligibility	764	767	who
I-eligibility	768	774	needed
I-eligibility	775	776	a
I-eligibility	777	783	course
I-eligibility	784	786	of
I-eligibility	787	796	radiation
I-eligibility	797	804	therapy
O	805	807	in
O	808	811	our
O	812	823	institution
O	824	828	were
O	829	837	enrolled
O	838	841	and
O	842	852	randomized
O	853	857	into
O	858	859	2
O	860	866	groups
O	867	868	1
O	869	873	with
O	874	878	Mebo
O	879	887	ointment
O	888	891	and
O	892	893	1
O	894	898	with
O	899	906	Biafine
O	907	912	cream
O	912	913	.

O	914	918	Both
O	919	930	medications
O	931	935	were
O	936	943	applied
O	944	949	twice
O	950	953	per
O	954	957	day
O	958	964	during
O	965	968	the
O	969	974	whole
O	975	981	period
O	982	984	of
O	985	994	treatment
O	995	998	and
O	999	1003	skin
O	1004	1013	reactions
O	1014	1017	and
O	1018	1025	related
O	1026	1034	symptoms
O	1035	1039	were
O	1040	1048	assessed
O	1049	1055	weekly
O	1056	1062	during
O	1063	1066	the
O	1067	1073	entire
O	1074	1080	course
O	1080	1081	.

O	1082	1089	Grading
O	1090	1092	of
O	1093	1097	skin
O	1098	1107	reactions
O	1108	1111	was
O	1112	1116	done
O	1117	1126	according
O	1127	1129	to
O	1130	1133	the
O	1134	1143	Radiation
O	1144	1151	Therapy
O	1152	1160	Oncology
O	1161	1166	Group
O	1167	1174	grading
O	1175	1181	system
O	1181	1182	.

O	1183	1190	Between
O	1191	1200	September
O	1201	1205	2015
O	1206	1209	and
O	1210	1213	May
O	1214	1218	2017
O	1218	1219	,
O	1220	1221	a
O	1222	1227	total
O	1228	1230	of
B-total-participants	1231	1234	161
O	1235	1243	patients
O	1244	1248	were
O	1249	1258	recruited
O	1259	1262	for
O	1263	1267	this
O	1268	1273	trial
O	1273	1274	.

O	1275	1279	Mean
O	1280	1283	age
O	1284	1287	was
O	1288	1295	similar
O	1296	1299	for
O	1300	1304	both
O	1305	1311	groups
O	1312	1313	(
B-age	1313	1315	50
I-age	1315	1316	.
I-age	1316	1318	19
I-age	1318	1319	±
I-age	1319	1321	12
I-age	1321	1322	.
I-age	1322	1324	57
O	1325	1327	vs
O	1327	1328	.
B-age	1329	1331	51
I-age	1331	1332	.
I-age	1332	1334	73
I-age	1334	1335	±
I-age	1335	1337	11
I-age	1337	1338	.
I-age	1338	1340	23
O	1340	1341	,
O	1342	1354	respectively
O	1354	1355	,
O	1356	1357	P
O	1357	1358	=
O	1358	1359	0
O	1359	1360	.
O	1360	1362	41
O	1362	1363	)
O	1363	1364	.

O	1365	1368	All
O	1369	1374	other
O	1375	1383	patients
O	1384	1387	and
O	1388	1397	treatment
O	1398	1413	characteristics
O	1414	1418	were
O	1419	1426	similar
O	1427	1429	in
O	1430	1434	both
O	1435	1441	groups
O	1441	1442	,
O	1443	1449	except
O	1450	1453	for
O	1454	1457	the
O	1458	1461	use
O	1462	1464	of
O	1465	1470	boost
O	1471	1472	(
O	1472	1474	82
O	1474	1475	.
O	1475	1476	7
O	1476	1477	%
O	1478	1480	in
O	1481	1484	the
O	1485	1492	Biafine
O	1493	1498	group
O	1499	1501	vs
O	1501	1502	.
O	1503	1505	36
O	1505	1506	.
O	1506	1507	7
O	1507	1508	%
O	1509	1511	in
O	1512	1516	Mebo
O	1517	1522	group
O	1522	1523	,
O	1524	1525	P
O	1525	1526	=
O	1526	1527	0
O	1527	1528	.
O	1528	1531	012
O	1531	1532	)
O	1532	1533	.

O	1534	1542	Analysis
O	1543	1546	was
O	1547	1551	done
O	1552	1555	for
O	1556	1565	reactions
O	1566	1574	recorded
O	1575	1581	before
O	1582	1585	the
O	1586	1595	beginning
O	1596	1598	of
O	1599	1602	the
O	1603	1608	boost
O	1609	1612	and
O	1613	1616	for
O	1617	1620	the
O	1621	1627	entire
O	1628	1634	course
O	1635	1644	including
O	1645	1648	the
O	1649	1654	boost
O	1654	1655	.

O	1656	1661	Using
O	1662	1672	univariate
O	1673	1676	and
O	1677	1689	multivariate
O	1690	1698	analysis
O	1698	1699	,
O	1700	1705	there
O	1706	1709	was
O	1710	1712	no
O	1713	1724	significant
O	1725	1735	difference
O	1736	1738	in
B-outcome	1739	1745	grades
I-outcome	1746	1747	2
I-outcome	1748	1751	and
I-outcome	1752	1753	3
I-outcome	1754	1764	dermatitis
O	1765	1772	between
O	1773	1776	the
O	1777	1778	2
O	1779	1785	groups
O	1785	1786	.

O	1787	1794	However
O	1794	1795	,
O	1796	1799	the
B-outcome	1800	1809	incidence
I-outcome	1810	1812	of
I-outcome	1813	1819	severe
I-outcome	1820	1828	pruritus
O	1829	1832	and
B-outcome	1833	1839	severe
I-outcome	1840	1845	local
I-outcome	1846	1850	skin
I-outcome	1851	1855	pain
O	1856	1860	were
O	1861	1865	both
O	1866	1879	significantly
O	1880	1887	reduced
O	1888	1890	in
O	1891	1894	the
O	1895	1899	Mebo
O	1900	1905	group
O	1906	1907	(
B-cv-bin-percent	1907	1909	14
I-cv-bin-percent	1909	1910	.
I-cv-bin-percent	1910	1911	1
I-cv-bin-percent	1911	1912	%
O	1913	1915	in
O	1916	1923	Biafine
O	1924	1926	vs
O	1926	1927	.
B-iv-bin-percent	1928	1929	2
I-iv-bin-percent	1929	1930	.
I-iv-bin-percent	1930	1931	9
I-iv-bin-percent	1931	1932	%
O	1933	1935	in
O	1936	1940	Mebo
O	1940	1941	,
O	1942	1943	P
O	1943	1944	=
O	1944	1945	0
O	1945	1946	.
O	1946	1949	016
B-outcome	1950	1953	for
I-outcome	1954	1962	pruritus
O	1963	1966	and
B-cv-bin-percent	1967	1969	11
I-cv-bin-percent	1969	1970	.
I-cv-bin-percent	1970	1971	5
I-cv-bin-percent	1971	1972	%
O	1973	1975	vs
O	1975	1976	.
B-iv-bin-percent	1977	1978	1
I-iv-bin-percent	1978	1979	.
I-iv-bin-percent	1979	1980	4
I-iv-bin-percent	1980	1981	%
O	1981	1982	,
O	1983	1995	respectively
O	1995	1996	,
O	1997	1998	P
O	1998	1999	=
O	1999	2000	0
O	2000	2001	.
O	2001	2003	02
B-outcome	2004	2007	for
I-outcome	2008	2014	severe
I-outcome	2015	2019	pain
O	2019	2020	)
O	2020	2021	.

O	2022	2026	This
O	2027	2032	study
O	2033	2039	showed
O	2040	2042	no
O	2043	2053	difference
O	2054	2061	between
O	2062	2066	Mebo
O	2067	2070	and
O	2071	2078	Biafine
O	2079	2081	in
O	2082	2085	the
O	2086	2095	incidence
O	2096	2099	and
O	2100	2108	severity
O	2109	2111	of
O	2112	2118	breast
O	2119	2123	skin
O	2124	2134	dermatitis
O	2135	2141	during
O	2142	2151	radiation
O	2152	2159	therapy
O	2159	2160	.

O	2161	2168	However
O	2168	2169	,
O	2170	2173	the
O	2174	2177	use
O	2178	2180	of
O	2181	2185	Mebo
O	2186	2194	ointment
O	2195	2198	was
O	2199	2209	associated
O	2210	2214	with
O	2215	2224	decreased
O	2225	2231	severe
O	2232	2240	pruritus
O	2241	2244	and
O	2245	2249	pain
O	2250	2255	which
O	2256	2261	could
O	2262	2272	positively
O	2273	2279	affect
O	2280	2287	patient
O	2288	2295	comfort
O	2296	2299	and
O	2300	2307	quality
O	2308	2310	of
O	2311	2315	life
O	2315	2316	.
